Alzheimer Disease Treatment Donanemab Receives FDA Approval; Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.

Media coverage

• Title	Alzheimer Disease Treatment Donanemab Receives FDA Approval; Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
  Media name/outlet	Psychiatric Times (MJH)
  Country/Territory	United States
  Date	1/07/24
  Persons	Howard Fillit